Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin

BACKGROUND: In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for major CV adverse events. However, there was...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollack, Pia S., Chadwick, Kristina D., Smith, David M., Billger, Martin, Hirshberg, Boaz, Iqbal, Nayyar, Boulton, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598064/
https://www.ncbi.nlm.nih.gov/pubmed/28903775
http://dx.doi.org/10.1186/s12933-017-0595-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598064/
https://www.ncbi.nlm.nih.gov/pubmed/28903775
http://dx.doi.org/10.1186/s12933-017-0595-6

Ejemplares similares